2. Loser: GlaxoSmithKline

Company: GlaxoSmithKline
Symbol: $GSK
Beginning Price: 1484.50 pence
Ending Price: 1347 pence
Loss: 9.26%

As February dawned at GlaxoSmithKline ($GSK), CEO Andrew Witty gave investors a pep talk. This would be the year that GSK returned to real sales growth--none of the "underlying" kind of growth you talk about during the worst of the patent cliff. "We feel like we are moving into a new era," Witty said at the time.

But the stars aligned in a different direction. Deep price cuts in Europe and generic competition in the U.S. offset solid growth in emerging markets and consumer healthcare, pushing second- and third-quarter revenues down instead of up. "[N]o cause for optimism," Witty said about Europe, adding that he hoped it wasn't "the new normal."

GSK has made forward strides--both in wrapping up old problems and taking on new opportunities. But since a high in August, the company's London-traded shares have been moving downward, with a big slide around the time those disappointing Q3 sales were announced. The question now is whether Witty's sunny outlook returns by year's end--and whether investors come along for the ride.

For more:
Pharma fights European austerity with product pullbacks
Exec says GSK is back on the straight and narrow
Glaxo sales slump in Europe, U.S. on price cuts, generics
Hang on just a bit longer for sales growth, GSK chief says

 

 

 

 

2. Loser: GlaxoSmithKline
Read more on

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.